No Pharma Money
All News & Reports

News

The week in prescription drug pricing: what moved, what it means for patients, and what comes next.

Stay Up To Date

News and reports from P4ADNow

News Jun 26, 2026

The Week in Review in Prescription Drug Pricing: Drug Costs Drive Midterms, Insulin Cap Gains GOP Support, and more

New polling from Axios-Ipsos shows that health care costs — particularly prescription drug prices — will be a defining issue in the 2026 midterms, with a majority of voters saying a candidate’s…

Read Article
News Jun 18, 2026

The Week in Review in Prescription Drug Pricing: Senate HELP Advances P4ADNow-Backed Bills, Closing Negotiation Loops, and more

Yesterday, the Senate HELP Committee advanced two bipartisan and P4ADNow-supported bills: The Biosimilar Red Tape Elimination Act (S. 1954), which would reduce unnecessary regulatory hurdles that…

Read Article
News Jun 12, 2026

The Week in Review in Prescription Drug Pricing: Senate HELP Markup on Affordability Bills Next Week, New Polling, Op-Ed, & more

The Senate HELP Committee is set to markup several bipartisan bills on Wednesday aimed at increasing competition and lowering drug prices.

Read Article
News Jun 5, 2026

The Week in Review in Prescription Drug Pricing: P4AD Releases New Video on The ETHIC Act, SCOTUS Protects Generic Competition, and more

Patients For Affordable Drugs Now released a new video featuring patient advocates and staff highlighting the bipartisan ETHIC Act ahead of this week’s House Judiciary hearing on patent law and prescription drug access.

Read Article
News May 29, 2026

The Week in Review in Prescription Drug Pricing: P4AD Joint ETHIC Letter, MFN Deals Put to the Test, New AARP Report, and more

This week, Patients For Affordable Drugs Now, AARP, and the ERISA Industry Committee (ERIC) sent a joint letter to congressional leadership urging Congress to pass the ETHIC Act.

Read Article
News May 22, 2026

The Week in Review in Prescription Drug Pricing: SCOTUS Denies Pharma Petitions, TrumpRx Expansion Raises Question, Pay-For-Delay Lawsuit, and more

The Supreme Court denied petitions from six major drugmakers — AstraZeneca, Bristol Myers Squibb, Janssen, Novartis, Novo Nordisk, and Boehringer Ingelheim— leaving in place lower court rulings that…

Read Article
News May 15, 2026

The Week in Review in Prescription Drug Pricing: Patent Barriers Delay Generic Ozempic in the U.S., Bipartisan Push Targets Pharmacy-PBM Integration, and Tariff Policy Drives Industry Workarounds – Not Lower Prices

Generic versions of semaglutide – the active ingredient in Ozempic and Wegovy – are beginning to enter the market in countries such as India and Canada.

Read Article
News May 8, 2026

The Week in Review in Prescription Drug Pricing: P4AD Reaches 40K Patient Stories, White House MFN Savings Estimates Raise Questions, and New Report Highlights Growing Use of Patent Tactics to Delay Competition

More than 40,000 vetted patient stories are now featured on P4AD’s interactive map, representing every state and congressional district and documenting the harm of high drug prices.

Read Article
News May 1, 2026

The Week in Review in Prescription Drug Pricing: SCOTUS Examines Skinny Labels, Rx Prices Remain Top Voter Concern, and more

The Supreme Court heard arguments this week in a case that could limit how and when lower-cost generics come to market.

Read Article
News Apr 24, 2026

The Week in Review in Prescription Drug Pricing: Regeneron Signs MFN Deal, Pharma Tops Q1 Healthcare Lobbying, Bipartisan Hill Pharma Probe, and more

Over the last two weeks, P4AD patient advocates from across the country traveled to Washington, D.C., to share what high drug prices mean in real terms — skipped doses, delayed care, and impossible financial tradeoffs.

Read Article

Stay Connected

Stay informed about the latest campaigns, policy developments, and ways to help lower prescription drug prices.